{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:34Z","timestamp":1793383174859,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In vivo, high cerebral amyloid-\u03b2 load has been associated with (i) reduced concentrations of A\u03b2<jats:sub>42<\/jats:sub> in cerebrospinal fluid and (ii) increased retention using amyloid-\u03b2 positron emission tomography. Although these two amyloid-\u03b2 biomarkers generally show good correspondence, ~\u200910\u201320% of cases have discordant results. To assess the consequences of having discordant amyloid-\u03b2 PET and CSF biomarkers on clinical features, biomarkers, and longitudinal cognitive trajectories.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 768 patients (194 with subjective cognitive decline (SCD), 127 mild cognitive impairment (MCI), 309 Alzheimer\u2019s dementia (AD), and 138 non-AD) who were categorized as concordant-negative (<jats:italic>n<\/jats:italic>\u2009=\u2009315, 41%), discordant (<jats:italic>n<\/jats:italic>\u2009=\u200997, 13%), or concordant-positive (<jats:italic>n<\/jats:italic>\u2009=\u2009356, 46%) based on CSF and PET results. We compared discordant with both concordant-negative and concordant-positive groups on demographics, clinical syndrome, apolipoprotein E (<jats:italic>APOE<\/jats:italic>) \u03b54 status, CSF tau, and clinical and neuropsychological progression.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found an increase from concordant-negative to discordant to concordant-positive in rates of <jats:italic>APOE<\/jats:italic> \u03b54 (28%, 55%, 70%, <jats:italic>Z<\/jats:italic>\u2009=\u2009\u2212\u200910.6, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), CSF total tau (25%, 45%, 78%, <jats:italic>Z<\/jats:italic>\u00a0=\u2009\u2212\u200913.7, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and phosphorylated tau (28%, 43%, 80%, <jats:italic>Z<\/jats:italic>\u2009=\u2009\u2212\u200913.7, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) positivity. In patients without dementia, linear mixed models showed that Mini-Mental State Examination and memory composite scores did not differ between concordant-negative (<jats:italic>\u03b2<\/jats:italic> [SE] \u2212\u20090.13[0.08], <jats:italic>P<\/jats:italic>\u2009=\u20090.09) and discordant (<jats:italic>\u03b2<\/jats:italic> 0.08[0.15], <jats:italic>P<\/jats:italic>\u2009=\u20090.15) patients (<jats:italic>P<\/jats:italic><jats:sub>interaction<\/jats:sub>\u2009=\u20090.19), while these scores declined in concordant-positive (<jats:italic>\u03b2<\/jats:italic> \u2212\u20090.75[0.08] patients (<jats:italic>P<\/jats:italic><jats:sub>interaction<\/jats:sub>\u2009&lt;\u20090.001). In patients with dementia, longitudinal cognitive scores were not affected by amyloid-\u03b2 biomarker concordance or discordance. Clinical progression rates from SCD to MCI or dementia (<jats:italic>P<\/jats:italic>\u2009=\u20090.01) and from MCI to dementia (<jats:italic>P<\/jats:italic>\u2009=\u20090.003) increased from concordant-negative to discordant to concordant-positive.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Discordant cases were intermediate to concordant-negative and concordant-positive patients in terms of genetic (<jats:italic>APOE<\/jats:italic> \u03b54) and CSF (tau) markers of AD. While biomarker agreement did not impact cognition in patients with dementia, discordant biomarkers are not benign in patients without dementia given their higher risk of clinical progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-019-0532-x","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T23:05:49Z","timestamp":1568243149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Discordant amyloid-\u03b2 PET and CSF biomarkers and its clinical consequences"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-5510","authenticated-orcid":false,"given":"Arno","family":"de Wilde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhan","family":"Reimand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Zwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N. M.","family":"van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"532_CR1","first-page":"nrdp201556","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Prim. 2015;1:nrdp201556.","journal-title":"Nat Rev Dis Prim"},{"key":"532_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388:505\u201317 Available from: \n                    http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673615011241\n                    \n                  .","journal-title":"Lancet"},{"key":"532_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2016.02.034","volume":"52","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, L\u00f6nneborg A, Boccardi M, Blennow K, Hansson O, for the of Biomarkers G. Clinical validity of cerebrospinal fluid A\u03b242, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:196\u2013213.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"532_CR4","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.jalz.2018.06.2855","volume":"14","author":"R Laforce","year":"2018","unstructured":"Laforce R, Soucy J, Sellami L, Dallaire-Th\u00e9roux C, Brunet F, Bergeron D, et al. Molecular imaging in dementia: past, present, and future. Alzheimers Dementia. 2018;14(11):1522\u201352.","journal-title":"Alzheimers Dementia"},{"key":"532_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"532_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dementia. 2011;7:270\u20139.","journal-title":"Alzheimers Dementia"},{"key":"532_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein S, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"532_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo J, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol"},{"key":"532_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pscychresns.2016.10.011","volume":"265","author":"CG Schipke","year":"2017","unstructured":"Schipke CG, Koglin N, Bullich S, Joachim L, Haas B, Seibyl J, et al. Correlation of florbetaben PET imaging and the amyloid peptide A\u00df42 in cerebrospinal fluid. Psychiatry Res Neuroimaging. 2017;265:98\u2013101.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"532_CR10","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/aww160","volume":"139","author":"A Leuzy","year":"2016","unstructured":"Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendon\u00e7a A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study. Brain. 2016;139:2540\u201353.","journal-title":"Brain."},{"key":"532_CR11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Initiative A, Minthon L, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240\u20139.","journal-title":"Neurology."},{"key":"532_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ. Aw L, et al. independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138:772\u201383.","journal-title":"Brain."},{"key":"532_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann Neurol. 2013;74:826\u201336.","journal-title":"Ann Neurol"},{"key":"532_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee S, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann Neurol. 2006;59:512\u20139.","journal-title":"Ann Neurol"},{"key":"532_CR15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O, Initiative A. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain. 2016;139:1226\u201336.","journal-title":"Brain."},{"key":"532_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091\u2013111.","journal-title":"J Alzheimers Dis"},{"key":"532_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jalz.2016.08.013","volume":"13","author":"AE Leeuwis","year":"2017","unstructured":"Leeuwis AE, Benedictus MR, Kuijer J, Binnewijzend M, Hooghiemstra AM, Verfaillie S, et al. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:531\u201340.","journal-title":"Alzheimers Dement"},{"key":"532_CR18","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/WNL.0000000000004802","volume":"90","author":"C Groot","year":"2017","unstructured":"Groot C, van Loenhoud AC, Barkhof F, van Berckel BN, Koene T, Teunissen CC, et al. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2017;90:e149\u201356.","journal-title":"Neurology."},{"key":"532_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","volume":"56","author":"C Mulder","year":"2010","unstructured":"Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-\u03b2 (1\u201342), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56:248\u201353.","journal-title":"Clin Chem"},{"key":"532_CR20","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.112.113654","volume":"54","author":"B van Berckel","year":"2013","unstructured":"van Berckel B, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using [11C]PIB: methodologic considerations. J Nucl Med. 2013;54:1570\u20136.","journal-title":"J Nucl Med"},{"key":"532_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg Y, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414\u201321.","journal-title":"Alzheimers Dement"},{"key":"532_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00259-012-2102-3","volume":"39","author":"R Ossenkoppele","year":"2012","unstructured":"Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2012;39:990\u20131000.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"532_CR23","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1212\/WNL.0000000000000432","volume":"82","author":"R Ossenkoppele","year":"2014","unstructured":"Ossenkoppele R, van der Flier WM, Verfaillie SC, Vrenken H, Versteeg A, van Schijndel RA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology. 2014;82:1768\u201375.","journal-title":"Neurology."},{"key":"532_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2016","unstructured":"Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2016;9:2.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"532_CR25","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"Arno de Wilde","year":"2018","unstructured":"de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062-70. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2018.1346\n                    \n                  .","journal-title":"JAMA Neurology"},{"key":"532_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jalz.2017.06.2264","volume":"14","author":"SE Schindler","year":"2018","unstructured":"Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, et al. Upward drift in cerebrospinal fluid amyloid \u03b2 42 assay values for more than 10 years. Alzheimers Dement. 2018;14:62\u201370.","journal-title":"Alzheimers Dement"},{"key":"532_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, Teunissen CE, Bouwman FH, Visser P-J, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid \u201cAlzheimer profile\u201d: Easily said, but what does it mean? Alzheimers Dementia. 2014;10:713\u2013723.e2.","journal-title":"Alzheimers Dementia"},{"key":"532_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2307\/3001775","volume":"11","author":"P Armitage","year":"1955","unstructured":"Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11:375\u201386.","journal-title":"Biometrics."},{"key":"532_CR29","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939\u201350.","journal-title":"JAMA."},{"key":"532_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"532_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Ch\u00e9telat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181\u201392.","journal-title":"Ann Neurol"},{"issue":"1","key":"532_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WAD.0000000000000239","volume":"32","author":"David Bergeron","year":"2018","unstructured":"Bergeron D, Ossenkoppele R, Laforce R. Evidence-based interpretation of amyloid-\u03b2 PET results: a Clinician\u2019s tool. Alzheimer Dis Assoc Disord. 2018;32(1):28-34. \n                    https:\/\/doi.org\/10.1097\/WAD.0000000000000239\n                    \n                  .","journal-title":"Alzheimer Disease & Associated Disorders"},{"key":"532_CR33","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1093\/brain\/aww193","volume":"139","author":"L Sarro","year":"2016","unstructured":"Sarro L, Senjem ML, Lundt ES, Przybelski SA, Lesnick TG, Graff-Radford J, et al. Amyloid-\u03b2 deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain. 2016;139:2740\u201350.","journal-title":"Brain."},{"key":"532_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/13554794.2015.1046458","volume":"22","author":"G Naasan","year":"2015","unstructured":"Naasan G, Rabinovici GD, Ghosh P, Elofson JD, Miller BL, Coppola G, et al. Amyloid in dementia associated with familial FTLD: not an innocent bystander. Neurocase. 2015;22:76\u201383.","journal-title":"Neurocase."},{"key":"532_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","volume":"11","author":"Y Stern","year":"2012","unstructured":"Stern Y. Cognitive reserve in ageing and Alzheimer\u2019s disease. Lancet Neurol. 2012;11:1006\u201312.","journal-title":"Lancet Neurol"},{"key":"532_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1212\/WNL.0b013e31825fdf18","volume":"79","author":"M Sch\u00f6ll","year":"2012","unstructured":"Sch\u00f6ll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, L\u00e5ngstr\u00f6m B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79:229\u201336.","journal-title":"Neurology."},{"key":"532_CR37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00401-003-0737-7","volume":"106","author":"O Yokota","year":"2003","unstructured":"Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Namba M, et al. Variability and heterogeneity in Alzheimer\u2019s disease with cotton wool plaques: a clinicopathological study of four autopsy cases. Acta Neuropathol. 2003;106:348\u201356.","journal-title":"Acta Neuropathol"},{"key":"532_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s &amp. Dementia. 2011;7:280\u201392.","journal-title":"Dementia."},{"key":"532_CR39","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3233\/JAD-132561","volume":"41","author":"M Zwan","year":"2014","unstructured":"Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis. 2014;41:801\u20137.","journal-title":"J Alzheimers Dis"},{"key":"532_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, et al. Reference measurement procedure for CSF amyloid beta (A\u03b2)1-42 and the CSF A\u03b21-42 \/A\u03b21-40 ratio - a cross-validation study against amyloid PET. J Neurochem. 2016;139:651\u20138.","journal-title":"J Neurochem"},{"key":"532_CR41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jalz.2017.01.010","volume":"13","author":"E Willemse","year":"2017","unstructured":"Willemse E, van Uffelen K, Brix B, Engelborghs S, Vanderstichele H, Teunissen C. How to handle adsorption of cerebrospinal fluid amyloid \u03b2 (1\u201342) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A\u03b242\/A\u03b240 ratio. Alzheimers Dement. 2017;13:885\u201392.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"532_CR42","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492.","journal-title":"JAMA Neurol"},{"key":"532_CR43","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/brain\/awv112","volume":"138","author":"S Villeneuve","year":"2015","unstructured":"Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020\u201333.","journal-title":"Brain."},{"key":"532_CR44","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2017","unstructured":"Tijms BM, Willemse EA, Zwan MD, Mulder SD, Visser P, van Berckel BN, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results. Clin Chem. 2017;64:576\u201385.","journal-title":"Clin Chem"},{"key":"532_CR45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/archneurol.2009.279","volume":"66","author":"NJ Cairns","year":"2009","unstructured":"Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid \u03b2 in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66:1557\u201362.","journal-title":"Arch Neurol"},{"key":"532_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med. 2009;1:371\u201380.","journal-title":"EMBO Mol Med"},{"key":"532_CR47","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"W Jagust","year":"2009","unstructured":"Jagust W, Landau S. Aw L, Trojanowski J, Koeppe R, Reiman E, et al. relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193\u20139.","journal-title":"Neurology."},{"key":"532_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","volume":"43","author":"E Morris","year":"2016","unstructured":"Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43:374\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"532_CR49","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.81","volume":"1","author":"N Mattsson","year":"2014","unstructured":"Mattsson N, Insel PS, Landau S, Jagust W, Donohue M. Aw L, et al. diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2014;1:534\u201343.","journal-title":"Ann Clin Transl Neurol"},{"key":"532_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1743-8454-7-10","volume":"7","author":"P Selnes","year":"2010","unstructured":"Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res. 2010;7:10.","journal-title":"Cerebrospinal Fluid Res"},{"issue":"10","key":"532_CR51","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","volume":"14","author":"Oskar Hansson","year":"2018","unstructured":"Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: a review. Alzheimers Dement. 2018;14(10):1313-33. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2018.05.008\n                    \n                  . Epub 2018 Jun 23.","journal-title":"Alzheimer's & Dementia"},{"key":"532_CR52","first-page":"1398","volume":"41","author":"T Landau","year":"2014","unstructured":"Landau T. Thurfjell L, hmidt, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. European Journal of Nuclear Medicine and. Mol Imaging. 2014;41:1398\u2013407.","journal-title":"Mol Imaging"},{"key":"532_CR53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2967\/jnumed.118.211532","volume":"60","author":"LE Collij","year":"2019","unstructured":"Collij LE, Konijnenberg E, Reimand J, ten Kate M, den Braber A, Alves I, et al. Assessing amyloid pathology in cognitively normal subjects using [18F]flutemetamol PET: comparing visual reads and quantitative methods. J Nucl Med. 2019;60:541\u20137.","journal-title":"J Nucl Med"},{"key":"532_CR54","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2967\/jnumed.114.139121","volume":"55","author":"MD Zwan","year":"2014","unstructured":"Zwan MD, Ossenkoppele R, Tolboom N, Beunders A, Kloet RW, Adriaanse SM, et al. Comparison of simplified parametric methods for visual interpretation of 11C-Pittsburgh compound-B PET images. J Nucl Med. 2014;55:1305\u20137.","journal-title":"J Nucl Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0532-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:22:22Z","timestamp":1599780142000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0532-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0532-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local medical ethics committee of VU University Medical Center has approved a general protocol for biobanking and using the clinical data for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}